(19)
(11) EP 3 496 754 A1

(12)

(43) Date of publication:
19.06.2019 Bulletin 2019/25

(21) Application number: 17840061.0

(22) Date of filing: 04.08.2017
(51) International Patent Classification (IPC): 
A61K 39/395(2006.01)
A61P 35/02(2006.01)
C07K 16/30(2006.01)
 A61K 47/51(2017.01)
A61P 35/04(2006.01)
C07K 16/28(2006.01)
(86) International application number:
PCT/US2017/045516
(87) International publication number:
WO 2018/031408 (15.02.2018 Gazette 2018/07)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
MA MD

(30) Priority: 11.08.2016 US 201662373591 P
30.09.2016 US 201615281453
30.11.2016 US 201662428231 P
11.04.2017 US 201715484308

(71) Applicant: Immunomedics, Inc.
Morris Plains, NJ 07950 (US)

(72) Inventors:
  • GOVINDAN, Serengulam V.
    Morris Plains New Jersey 07950 (US)
  • CARDILLO, Thomas M.
    Morris Plains New Jersey 07950 (US)
  • GOLDENBERG, David M.
    Morris Plains New Jersey 07950 (US)

(74) Representative: Bohmann, Armin K. 
Bohmann Anwaltssozietät Nymphenburger Straße 1
80335 München
80335 München (DE)

   


(54) EFFICACY OF ANTI-HLA-DR ANTIBODY DRUG CONJUGATE IMMU-140 (hL243-CL2A-SN-38) IN HLA-DR POSITIVE CANCERS